Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.80 Consensus Price Target from Analysts

Schrödinger, Inc. (NASDAQ:SDGR) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $32.80.

Several research analysts recently issued reports on the stock. Piper Sandler reduced their price target on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. KeyCorp upped their price target on shares of Schrödinger from $30.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th.

Schrödinger Stock Up 3.5%

Shares of NASDAQ SDGR opened at $21.22 on Friday. The firm’s 50-day simple moving average is $22.80 and its 200 day simple moving average is $22.07. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -9.07 and a beta of 1.84. Schrödinger has a 12-month low of $16.60 and a 12-month high of $28.47.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.01). The company had revenue of $59.55 million for the quarter, compared to analyst estimates of $54.60 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.86) EPS. On average, equities analysts expect that Schrödinger will post -2.37 earnings per share for the current year.

Insider Buying and Selling at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares in the company, valued at approximately $599,357.44. This represents a 16.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Karen Akinsanya sold 16,723 shares of the company’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $25.09, for a total transaction of $419,580.07. Following the transaction, the insider now owns 15,625 shares in the company, valued at approximately $392,031.25. The trade was a 51.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new position in Schrödinger during the 4th quarter valued at about $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Schrödinger in the 1st quarter valued at about $37,000. Paradigm Asset Management Co. LLC bought a new stake in shares of Schrödinger in the 4th quarter valued at about $50,000. PNC Financial Services Group Inc. increased its stake in shares of Schrödinger by 29.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,956 shares of the company’s stock valued at $58,000 after acquiring an additional 680 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Schrödinger by 73.9% in the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after acquiring an additional 1,853 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.